Heat Biologics rises as future arm Elusys finalizes $80 mln U.S. govt contract

Scorpius Holdings

31/01/2022 14:36

** Heat Biologics Inc's shares  HTBX.O  rise 1.1% to $2.66
    ** Elusys Therapeutics, which is merging with HTBX's unit,
finalizes U.S. government contract to deliver Anthim, its
treatment for inhalation anthrax  urn:newsml:reuters.com:*:nGNX8D3jRp
    ** Total value of contract for Anthim will be over $80
million; full delivery expected by first half of 2023
    ** Elusys Therapeutics merger with HTBX expected in Q1 2022
    ** All four brokerages covering HTBX rate the stock "buy";
their median PT is $19.50 - Refinitiv data
    ** Up to Friday's close, stock had fallen 13.5% YTD

 (Reporting by Leroy Leo)
 ((Leroy.Dsouza@thomsonreuters.com;))